Olema Oncology
Kate Swearingen's work experience spans over several years in various roles within the pharmaceutical and clinical research industry. Kate has held positions such as Senior Director of Program and Clinical Alliance Management at Olema Oncology, Director of Program Management at Nektar Therapeutics, Senior Clinical Trial Manager at Ultragenyx Pharmaceutical Inc., and Senior Project Manager at Novella Clinical, Inc. Kate has also worked as a Project Manager at Health Decisions and in roles ranging from Project Coordinator to Associate Project Manager at Rho and as a Site Relations Analyst at PPD. Throughout their career, Kate has demonstrated expertise in project management, leadership, and ensuring adherence to industry regulations.
Kate Swearingen completed their Bachelor of Arts in Art History and Religious Studies at Texas Christian University from 1999 to 2004. Kate then pursued a Master of Public Health at the University of North Carolina at Chapel Hill, earning their degree in Public Health in 2007. Kate later obtained a Certificate in Core Public Health Concepts from the same institution in 2010. Currently, they are working towards a Master of Business Administration in Biotechnology at San Francisco State University, with an expected completion year of 2024. In 2012, Kate also obtained the Project Management Professional certification from the Project Management Institute.
Olema Oncology
Olema Oncology is a biopharmaceutical company developing innovative targeted therapies for women’s cancers. Their lead program, OP-1250, a potential best-in-class complete estrogen receptor antagonist (CERAN), is in development to treat estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema recently initiated a Phase 1/2 dose-escalation and expansion clinical trial of OP-1250. They are supported in their mission by experienced and accomplished scientists and board members, leading healthcare investors and some of the most innovative pharma companies.